1. Home
  2. DPG vs ALT Comparison

DPG vs ALT Comparison

Compare DPG & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DPG
  • ALT
  • Stock Information
  • Founded
  • DPG 2011
  • ALT 1997
  • Country
  • DPG United States
  • ALT United States
  • Employees
  • DPG N/A
  • ALT N/A
  • Industry
  • DPG Trusts Except Educational Religious and Charitable
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • DPG Finance
  • ALT Health Care
  • Exchange
  • DPG Nasdaq
  • ALT Nasdaq
  • Market Cap
  • DPG 465.0M
  • ALT 472.3M
  • IPO Year
  • DPG N/A
  • ALT N/A
  • Fundamental
  • Price
  • DPG $12.28
  • ALT $5.40
  • Analyst Decision
  • DPG
  • ALT Strong Buy
  • Analyst Count
  • DPG 0
  • ALT 7
  • Target Price
  • DPG N/A
  • ALT $21.00
  • AVG Volume (30 Days)
  • DPG 150.1K
  • ALT 2.5M
  • Earning Date
  • DPG 01-01-0001
  • ALT 05-13-2025
  • Dividend Yield
  • DPG 9.09%
  • ALT N/A
  • EPS Growth
  • DPG N/A
  • ALT N/A
  • EPS
  • DPG N/A
  • ALT N/A
  • Revenue
  • DPG N/A
  • ALT $20,000.00
  • Revenue This Year
  • DPG N/A
  • ALT $4,108.32
  • Revenue Next Year
  • DPG N/A
  • ALT $3,900.06
  • P/E Ratio
  • DPG N/A
  • ALT N/A
  • Revenue Growth
  • DPG N/A
  • ALT N/A
  • 52 Week Low
  • DPG $7.90
  • ALT $3.55
  • 52 Week High
  • DPG $13.58
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • DPG 53.00
  • ALT 52.71
  • Support Level
  • DPG $12.15
  • ALT $5.38
  • Resistance Level
  • DPG $12.45
  • ALT $5.81
  • Average True Range (ATR)
  • DPG 0.21
  • ALT 0.35
  • MACD
  • DPG -0.02
  • ALT -0.03
  • Stochastic Oscillator
  • DPG 61.43
  • ALT 34.18

About DPG Duff & Phelps Utility and Infrastructure Fund Inc.

Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting primarily from a high level of current income, with an emphasis on providing tax-advantaged dividend income.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: